Acute management of MOGAD: therapeutic choices and clinical outcomes

Edgar Carnero Contentti; Eoin P. Flanagan; Ethel Ciampi

doi:10.1080/14728214.2026.2689745

June 13, 2026Expert Opinion on Emerging Drugs

Acute management of MOGAD: therapeutic choices and clinical outcomes

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness of various treatment options for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Monitored clinical outcomes over a defined follow-up period
Analyzed data from multiple centers for comprehensive results.
Identified significant improvements in clinical outcomes for patients receiving specific therapies
Notable response rates were observed among treated groups, indicating effective management strategies
Details of effect sizes and statistical significance provided for major therapeutic interventions.

Implication

Reveals the effects of different treatments on clinical outcomes in MOGAD, suggesting optimal therapeutic choices.

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is now recognized as a distinct inflammatory demyelinating disorder of the central nervous system (CNS), separate fr...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Contentti et al. (2026) studied this question.

synapsesocial.com/papers/6a2f96eca1cfeec49082816f https://doi.org/10.1080/14728214.2026.2689745

View at Publisher

Ask AI

Bookmark

Share

Acute management of MOGAD: therapeutic choices and clinical outcomes

Key Points

Implication

Abstract

Discussion

Cite This Study

Acute management of MOGAD: therapeutic choices and clinical outcomes

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Expert Opinion on Emerging Drugs

Keep reading

More related papers

More from Expert Opinion on Emerging Drugs